Abstract
BMS 181184 (BMS), an analogue of pradimicin, was administered intravenously to neutropenic mice infected with either a fluconazole- susceptible or a fluconazole-resistant clinical isolate of Candida tropicalis. BMS prolonged survival at doses >3 mg kg-1 day-1, and at higher doses reduced tissue counts in mice. BMS was less potent mg for mg than amphotericin B. Combined BMS and amphotericin B were no more effective than either of the individual drugs.
Original language | English (US) |
---|---|
Pages (from-to) | 181-184 |
Number of pages | 4 |
Journal | Medical mycology |
Volume | 36 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1998 |
Keywords
- BMS
- Candida tropicalis
- Fluconazole
- Mouse model
- Pradimicin
ASJC Scopus subject areas
- Infectious Diseases